Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

• Status: Completed
• Trial end date: 2018-10-16
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this survey is to confirm the safety of Suglat Tablets

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Ipragliflozin

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes who first use Suglat Tablets during the period from July 17, 2014 to July 16, 2015

Exclusion Criteria:

• off-label use patients